Market Cap (In TWD)
9.25 Billion
Revenue (In TWD)
469.27 Million
Net Income (In TWD)
382.61 Million
Avg. Volume
286.09 Thousand
- Currency
- TWD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 135.0-465.0
- PE
- -
- EPS
- -
- Beta Value
- 0.115
- ISIN
- TW0006785009
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Dr. Yung-Shun Wen Ph.D.
- Employee Count
- -
- Website
- https://www.alarpharm.com
- Ipo Date
- 2020-10-05
- Details
- Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
More Stocks
-
1802
-
YOU
-
ACGL
-
9536
-
AEVSAevis Victoria SA
AEVS
-
CLVSFCellaVision AB (publ)
CLVSF
-
3631
-
RIOT